Shenzhen Hepalink Pharmaceutical Group Co Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Hepalink Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Changjiang Runfa Medicine Co Ltd
sales of 4.67 billion Chinese Renmimbi [US$668.53 million]
of which 72%
ChangChun High New Technology Industries
(5.32 billion Chinese Renmimbi [US$761.35 million]
of which 89%
was Medication), and
Shandong Xinhua Pharmaceutical Company Limited
(5.21 billion Chinese Renmimbi [US$744.93 million]
of which 49%
During the year ended December of 2018, sales at
Shenzhen Hepalink Pharmaceutical Group Co Ltd were 4.81 billion Chinese Renmimbi (US$688.67 million).
increase of 80.3%
versus 2017, when the company's sales were 2.67 billion Chinese Renmimbi.
Sales of Pharmaceutical Manufacturing saw an increase
80.3% in 2018, from
2.67 billion Chinese Renmimbi to 4.81 billion Chinese Renmimbi.